Introduction
The estimation of left ventricular (LV) ejection fraction (EF) for detecting anthracycline (ANT)-related cardiotoxicity in cancer patients has gained importance over time and nowadays represents the most widely used technique for monitoring cardiac changes during and after chemotherapy. [1] [2] [3] Although EF is a recognized prognostic indicator in the general population, its diagnostic accuracy for early detection of cardiotoxicity remains controversial. [4] [5] [6] EF by 2D echocardiography often fails in detecting subtle changes in LV systolic function for several reasons, including the need of geometrical assumptions for calculations, possible inadequate visualization of LV apex, impossibility in identifying marginal regional wall motion abnormalities, and intrinsic variability of measurements. [7] [8] [9] In addition to method problems, a detectable drop of EF occurs only after the loss of large amount of myocardial tissue. Thus, a reduced EF after chemotherapy is often a sign of an already extensive myocardial damage and overt heart failure. 10, 11 Recently, 2D speckle tracking echocardiography (STE) 12, 13 has been investigated in the setting of cancer patients. 2D STE allows to quantify longitudinal, circumferential, and radial strain parameters. Alterations in parameters of 2D STE have been shown to precede decrease in EF during and after ANT chemotherapy. 5, 6, [14] [15] [16] [17] [18] The optimal 2D STE parameter to predict cardiotoxicity has been suggested to be global longitudinal strain (GLS) 16 : an average of 10-20% decrease in GLS has been observed during treatment and an 'in-treatment' reduction of GLS > 15% is likely to be of clinical significance. 16 Long-term follow-up studies after ANT chemotherapy have also shown that GLS is more significantly reduced than EF, in comparison with age-matched controls. 19 Accordingly, ASE/EACVI Expert Consensus strongly supports a GLS-based follow-up of adults during and after cancer therapy. 20 Also real-time 3D echocardiography has been shown to be useful in this clinical setting, with an accuracy in detecting EF < 50% which is comparable to cardiac magnetic resonance (CMR) in childhood survivors undiagnosed for cardiotoxicity by standard 2D echo assessment. 21 3D echocardiography has also demonstrated to be the most reproducible ultrasound technique for LV volume measurements and EF over 1-year follow-up in patients undergoing cancer chemotherapy. 9 Technological progress of 3D echo has recently developed softwares that allow to obtain a simultaneous quantitative assessment of all the strain components. 12 The main advantage of 3D STE corresponds to the possibility of analysing the whole left ventricle from a unique data volume and considerably reducing the time of analysis in comparison with the more time-consuming 2D STE. 22 The advantages of 3D STE have been poorly explored in cancer patients. Accordingly, the present study was designed to compare either 2D STE and 3D volumetric and 3D STE for detecting early LV dysfunction with standard echocardiographic indices of LV function in breast cancer patients undergoing ANT chemotherapy.
Methods

Study population
Consecutive asymptomatic women with diagnosis of breast cancer, scheduled to receive ANT (mainly FEC protocol: fluoruracile þ epirubicin þ cyclophosphamide; 3-6 cycles) ( Figure 1 ) and free of cardiac symptoms/signs including those attributable to heart failure were prospectively involved in the study after obtaining their written informed consent. A detailed cardiac history was collected at the recruitment, including cardiovascular risk factors. Clinical history, physical and echocardiographic exams were used to establish their eligibility. Exclusion criteria included patients with ascertained coronary artery disease and previous myocardial infarction, arterial hypertension, primary cardiomyopathies, 2D echocardiographic wall motion abnormalities, rhythm other than sinus, prosthetic valves or pacemakers, echocardiographic EF < 50% before chemotherapy, more than mild valvular stenosis or regurgitation, assumption of cardiac medications, and standard echo images of inadequate quality.
The first echocardiographic exam was included in the oncologic evaluation of the patients at first diagnosis of breast cancer, thus before starting radiotherapy and chemotherapy and the eventual mastectomy (ideally 1 day before). The follow-up echo was performed after completion of ANT chemotherapy cycles and always before the beginning of Figure 1 Chemotherapy protocol in the breast cancer patients of our study population. Three to 6 cycles (every 21 days).
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trastuzumab or other chronic chemotherapeutic agents. A detailed record of the administered cumulative ANT dose was documented. Height was measured at baseline, while weight and blood pressure were measured at the time of each echo exam.
Procedures
Standard Doppler echo exams were performed using a 2.5 MHz transducer with harmonic capability and a 3D volumetric transducer for realtime echocardiographic data set acquisition of the left ventricle by of a Vivid E9 ultrasound machine (GE Healthcare, Horten, Norway).
Standard echo-Doppler examination
2D and Doppler standards of our laboratory have been previously described. 23 The quantitative analysis of the left ventricle was performed as recommended. 24 2D EF was computed from LV end-diastolic and endsystolic volumes calculated according to the modified Simpson rule in apical four and two chambers views. LV mass was calculated using standard approach and indexed for height powered to 2.7. 25 Left atrial volume (arealength method in apical four and two chamber views) was indexed for body surface area. 24 Transmitral Doppler inflow and pulsed Tissue Doppler were recorded in apical four chamber view. The average of early diastolic peak velocity (e') of septal and lateral mitral annulus velocity was computed and the ratio of transmitral peak early velocity (E) to average e' (E/e' ratio) calculated as a reliable estimate of LV diastolic function. 26 A cut-point value of 14 of E/e' ratio was considered as indicative of a pathologic LV filling pressure increase.
26
2D strain, 3D volumetric, and 3D strain 2D and 3D STE were performed and analysed according to standardized procedures. 27 Data sets were stored digitally in raw data and exported to a workstation (Echopac PC, 110.1.1, GE Healthcare) equipped with a commercially available software (4D Auto LVQ software, GE Healthcare) for offline quantification of 2D derived GLS, 3D volumetric, and 3D STE analysis. 2D GLS was calculated as the average of 17 myocardial segments recorded in the three apical views. A percent reduction of GLS between post-ANT exam and baseline > 15% was considered to be indicative of subclinical cardiotoxicity according to the ASE/EACVI Expert Consensus,
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By3D echocardiography, LV end-diastolic volume (EDV) and endsystolic volume (ESV), sphericity index, stroke volume (SV, mL = EDV -ESV), cardiac output (CO, L/m = SV Â heart rate) and EF (%, EDV -ESV/ EDV Â 100) were obtained. 3D LV mass was also estimated and indexed for height powered to 2.7. 3D GLS, global circumferential strain (GCS), global area strain (GAS), and global radial strain (GRS) were also calculated as weighted averages of the regional values from the 17 myocardial segments. By using both 2D and 3D STE, the results of the rejected segments were removed and excluded in the calculation of global strain values, and if more than three segments were rejected, global strain values were not calculated. In the present study, patients with > _ 3 rejected segments were not considered feasible and not considered for statistical analysis.
Statistical analyses
Statistical analysis was performed by SPSS package release 12 (SPSS Inc, Chicago, IL, USA). Data are presented as mean values ± standard deviation. Student t-test for paired data was used to compare baseline and post-ANT results. The null hypothesis was rejected at a two-tailed P < 0.05.
Results
After excluding 15 patients [5 for arterial hypertension, 4 for coronary artery disease, 3 for low EF (<50%), 2 for more than more than mild mitral regurgitation, and 1 for rhythm disorders corresponding to frequent ventricular premature beats], 100 patients entered the study. Of note, no patient was excluded because of inadequate standard echocardiographic images at baseline. None of the patients dropped out from ANT chemotherapy because of cardiac symptoms or was taking cardiac drugs at the time of post-ANT echo exam. None had cardiac symptoms or were on cardiac medication at the time of the baseline evaluation and at follow-up exam. The baseline characteristics of the study population are summarized in Table 1 . ANT cumulative dose during chemotherapy was 505.4 ± 110.9 mg/m 2 (range = 260-1150). Ten of the 100 patients had begun radiotherapy at the time of post-ANT echocardiogram (7.7 ± 1.5 days before the echo exam performance). The follow-up period from the beginning of cancer therapy was 127 ± 18 days. The feasibility of standard echocardiography, 2D GLS, 3D volumetric, and 3D STE before and after ANT are depicted in Figure 2 . Feasibility of standard echo was optimal (100%), both at baseline and after ANT. The feasibility of 2D GLS was also very good, without difference between baseline and ANT. Reasons of 2D GLS unfeasibility after ANT of 10 of 100 patients included concomitant radiotherapy (n = 5), left mastectomy (n = 1), and the combination of left mastectomy þ left breast prosthesis (n = 4). Feasibility of both 3D volumetric and 3D STE was suboptimal at baseline and further reduced after ANT (P < 0.0002 and P < 0.0001 respectively). Supplementary data online, Table S1 displays possible factors of post-ANT unfeasibility in individual patients who presented suboptimal 3D strain images. With general factors (age, overweight, and smoking), specific factors included concomitant radiotherapy (n = 6). left mastectomy (n = 1), a combination of left mastectomy þ left breast prosthesis (n = 4), and a triple association radiotherapy þ left mastectomy þ left prosthesis (n = 2). Table 2 reports the analysis of standard Doppler-echo and GLS. No significant difference in parameters of LV structure and 2D EF were found. Among echo-Doppler parameters, only E/e' ratio (P = 0.006) and GLS (both P = 0.004) were significantly altered after ANT. Of note, 39% of the patients showed an increase of E/e' ratio but none overcame the pathologic cut-point value of 14 after ANT therapy. The percent reduction of GLS between post-ANT exam and baseline was > 15% in 17 of our patients. Table 3 presents the 3D volumetric and 3D STE analysis. LV endsystolic volume and EF (both P < 0.01) were marginally but significantly reduced after ANT. All 3D strain parameters were reduced after ANT (P < 0.0001 for GCS and GAS; P < 0.001 for GLS and P < 0.002 for GRS). Worthy of note, no patient had 2D derived EF < 50% after ANT but 4 on 67 patients (or 6.0%) with an available 3D echo before and after ANT had 3D derived EF < 50% after ANT (P = 0.016). In these 4 patients baseline to post-ANT changes of EF were the following: 63-44% by 3D and 70-58% by 2D respectively, 68-47% and 64-61%, 52-46% and 65-59%, 52-47%, and 56-55%. Figure 3 depicts 3D volumetric and 3D strain components at baseline and after ANT in one of our patients.
Discussion
In the present study, we tested the diagnostic value of both 2D derived GLS and (both volumetric and strain) 3D echocardiography in detecting early changes of LV systolic function in breast cancer patients undergoing ANT chemotherapy. To the best of our knowledge, 3D STE has never been used before for serial assessment in this clinical setting. The findings of the study demonstrate that: (i) among standard echo-Doppler parameters, E/e' ratio more than 2D EF is able to detect early changes of LV function, (ii) 2D derived GLS also allows to detect a possible subclinical alteration of LV longitudinal function, (iii) 3D volumetric assessment unmasks EF changes that cannot be identified by the simple 2D quantification, (iv) 3D derived STE demonstrates that the deterioration of LV myocardial mechanics include all the strain components, with the greatest effect for GCS and GAS, (v) the suboptimal feasibility of 3D echocardiography-and in particular of 3D STE-emerges as a main disadvantage as strongly limits the routine applicability of this technique in breast cancer patients.
The early detection of ANT-related cardiotoxicity (type 1 cardiotoxicity, cumulative and dose related, permanent and irreversible) is a mainstay in cancer patients, in order to initiate timely cardiac therapeutic support and possibly prevent more advanced stages of LV dysfunction. 7, 18, 28 This issue is particularly crucial in breast cancer patients who are HER2-positive and are candidate to be addressed towards concurrent or sequential adjuvant therapy with trastuzumab, a drug which can induce type 2 cardiotoxicity (not dose related, often reversible). 20 2D STE has been used successfully to identify early changes of myocardial function and to predict subsequent global LV chamber dysfunction, such as EF reduction. 5, 6, [14] [15] [16] [17] [18] It has also been demonstrated to be more accurate than 2D EF for detecting subclinical cardiotoxicity. 19, 20 Similarly, 3D echo, the most reproducible ultrasound tool for LV volume and EF measurements in cancer patients undergoing chemotherapy, 9 has shown ability to identify subjects with EF < 50%, with similar accuracy of CMR. 21 Which standard echo-Doppler parameter could be considered optimal for early detection of cardiotoxicity is still debated. In relation with the recognized limits of 2D EF, additional parameters of LV systolic longitudinal function (i.e. M-mode displacement of mitral annulus and Tissue Doppler derived systolic velocity of the mitral annulus) [29] [30] [31] [32] and of LV diastolic function 17,31-36 have been explored.
Globally, these parameters do not exhibit convincing superiority when compared with 2D EF. In our analysis, 2D EF was not significantly modified and a clear-cut reduced 2D EF (<50%) was not found in any patient after ANT. In contrast, E/e' ratio, a recognized marker of elevated LV diastolic dysfunction, 26 being also a prognosticator after myocardial infarction 37 and in arterial hypertension, 38 appeared to be significantly increased after ANT in 39% of our patients. These findings are consistent with a position statement from the Heart Failure Association of European Society of Cardiology, which suggest to consider LV diastolic abnormalities as early signs of ANT-induced LV dysfunction.
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2D derived GLS showed similar results, it being significantly reduced by ANT even in absence of symptoms/signs of heart failure. The small changes of 2D GLS we found can be considered clinically valuable in relation with GLS variability which has been demonstrated to be substantially lower in comparison with that of 2D EF. 40 This finding is also largely confirmatory of previous studies 5, 6, [14] [15] [16] [17] [18] [19] [20] and appears to be consistent with the recent trend of the scientific literature 41 and ASE/EACVI recommendations on the use of cardiac imaging in patients undergoing cancer therapy. 20 Of note, after ANT 17% of our patients achieved ASE/EACVI criteria of subclinical cardiotoxicity, a percentage that should not be underestimated.
3D volumetric assessment has already demonstrated better accuracy than 2D echo for identification of EF < 50% at CMR in ANTtreated childhood cancer. 21 This finding is indirectly confirmed in our breast cancer patients. 3D EF was marginally but significantly reduced and some patients (4 on 67 of patients with available 3D echo before Figure 3 Real-time 3D volumetric and 3D STE (bull's eye depiction) at baseline and after ANT in a breast cancer patient. 3D derived EF and strain components are all reduced after ANT chemotherapy. Although 3D EF was not substantially modified, changes of strain components can be considered clinically valuable. CO, cardiac output; EDV, end-diastolic volume; EF, ejection fraction; ESV, endsystolic volume; GAS, global area strain; GCS, global circumferential strain; GLS, global circumferential strain; GRS, global radial strain; HR, heart rate; SI, sphericity index, SV, stroke volume. The data of the present study also demonstrate that all 3D derived LV strain components were significantly altered after ANT. This abnormality was particularly evident for GCS and GAS. The reduction of 3D GLS after ANT is consistent with the large body of evidence obtained by using 2D STE. 5, 6, [14] [15] [16] [17] [18] [19] [20] Also the reduction of CGS 6,15 and GRS 5, 6, 14, 15 is in agreement with 2D STE observations in ANTtreated cancer patients. Our results indirectly suggest that all myocardial layers can be involved by ANT. The modification evidenced in GAS, a novel 3D STE parameter that includes the deformations of both subendocardial and midwall layers, is of particular interest. GAS has already shown to be a comprehensive parameter of LV myocardial dysfunction in patients with coronary artery disease 43 and arterial hypertension. 27 While we note the ability of three dimensional echocardiography (3DE) in magnifying early alteration of LV function in our population, it is also important to consider how in the present study the feasibility of 3D echo was relatively poor, at baseline and in particular after ANT (66% for 3D volumetric and 60% for 3D STE). Combined with factors affecting echo performance in the general population (mainly aging and overweight), we could isolate specific factors affecting the quality of imaging in our breast cancer patients, including concomitant radiotherapy, left mastectomy ad left breast prosthesis, which show a detrimental impact in particular on 3D strain.
Study limitations
The main limitation of the study could eventually correspond to the short follow-up duration. This had obvious reflections on the absence of clinical events as well as on the lack of development of overt cardiotoxicity and low rate of reduction in LV systolic function. In particular, a longer follow-up could have probably pointed out that even a small change in strain or EF as shown in our study would be of clinical importance. Accordingly, it was not possible to establish the predictive value of the identified 2D or 3D signs of subclinical cardiac damage. However, we intentionally studied the effect of ANT cycles which have a well-defined time duration and can predispose to subsequent cardiotoxicity due to trastuzumab. Cardiotoxicity types 1 and 2 can in fact potentiate their detrimental effects one each other exposing patients to an exponential risk of LV dysfunction. 20 Accordingly, the detection of subclinical cardiotoxicity at the end of ANT cycles can be considered a valuable goal in order to initiate early cardioprotective therapy before the onset of overt heart failure.
Clinical implications
The present study demonstrates that 3D echocardiography could potentially improve the ability for detecting early, subclinical abnormalities of LV function in breast cancer patients undergoing ANT therapy. However, its suboptimal feasibility, which involves mainly 3D STE after ANT, particularly comprising patients with left side breast (left mastectomy and/or left prosthesis) and the additional effect of radiotherapy, strongly limits its applicability in this clinical setting. For this type of patients, E/e' ratio and 2D GLS can provide acceptable better accuracy than 2D EF in the detection of early LV dysfunction. Overall, our findings confirm the ability of advanced echo techniques in detecting subclinical cardiotoxicity, a possible advantage for prevention of overt LV dysfunction through timely initiation of cardioprotective therapy. 44 
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